MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1158/2326-6066.cir-24-0876

Медицинская библиотека · Cancer immunology research · 2025

Secretion of a VEGF-Blocking scFv Enhances CAR T-cell Potency.

Supper Valentina M, Donner Hannah, Birocchi Filippo, Bratt Alexandra, Escobar Giulia, Kann Michael C, Park Sangwoo, Martin Grace, Korell Felix, Takei Hana, Armstrong Alexander, Parker Aiyana, Salas-Benito Diego, Darnell Eli P, Bailey Stefanie R, Kienka Tamina, Philips Merle, Bouffard Amanda, Goncalves Sadie, Choi Bryan D, Haradhvala Nicholas J, Maus Marcela V, Leick Mark B

СтатьяПеревод в очереди

Аннотация

Chimeric antigen receptor (CAR) T-cell therapy is an effective treatment strategy for B-cell malignancies; however, its efficacy in solid tumors remains limited. VEGF-targeted drugs are used as antitumor agents to target abnormal tumor vasculature; however, toxicities associated with systemic VEGF blockade limit their maximal therapeutic benefit. Increasing evidence suggests a role for VEGF in the immunosuppressive tumor microenvironment, including through direct induction of T cell-effector dysfunction. In this study, we show that CAR T cells from patients treated with FDA-approved CAR T-cell products express members of the VEGF signaling pathway, and this expression is correlated with patient nonresponse. To overcome putative VEGF-induced CAR T-cell dysfunction and deliver local VEGF blockade, we generated CAR T cells that secrete a VEGF-targeting single-chain variable fragment to block T-cell and tumor-derived VEGF within the tumor microenvironment. These CAR T cells potently inhibited VEGF signaling and angiogenesis in vitro and exhibited enhanced activation, cytotoxicity, proliferation, and effector function across different antigen and solid tumor contexts. VEGF single-chain variable fragment-secreting CAR T cells showed improved tumor control in immunocompromised murine metastatic and orthotopic models of ovarian and lung cancer. These findings suggest that CAR T cell-secreted VEGF blockade augments CAR T-cell performance, inhibits VEGF without systemic toxicity, and warrants further development.

Для цитирования: Supper Valentina M, Donner Hannah, Birocchi Filippo, Bratt Alexandra, Escobar Giulia, Kann Michael C, Park Sangwoo, Martin Grace, Korell Felix, Takei Hana, Armstrong Alexander, Parker Aiyana, Salas-Benito Diego, Darnell Eli P, Bailey Stefanie R, Kienka Tamina, Philips Merle, Bouffard Amanda, Goncalves Sadie, Choi Bryan D, Haradhvala Nicholas J, Maus Marcela V, Leick Mark B. Secretion of a VEGF-Blocking scFv Enhances CAR T-cell Potency.. Cancer immunology research. 2025. DOI: 10.1158/2326-6066.cir-24-0876.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.